세계의 유도만능줄기세포(iPSC) 생산 시장 규모, 점유율 및 동향 분석 보고서 : 공정별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유도만능줄기세포(iPSC) 생산 시장 성장 및 동향 :

Grand View Research, Inc의 최신 보고서에 따르면, 세계 유도만능줄기세포(iPSC) 생산(iPSC) 시장 규모는 2024년부터 2030년까지 9.44%의 연평균 복합 성장률(CAGR)로 2030년까지 27억 6,000만 달러에 달할 것으로 예상됩니다.

배아줄기세포(ESC)에 비해 인공만능줄기세포(iPSC)에 대한 수요가 증가하면서 시장을 주도하고 있습니다. 줄기세포와 관련된 윤리적 문제가 없습니다는 점, 개인 맞춤형 치료가 가능하다는 점, 세포를 이용한 연구의 유연성 등의 장점은 시장 성장에 유리한 시나리오를 만들어내고 있습니다. 또한, 만성질환의 유행도 유도만능줄기세포(iPSC) 생산 시장의 성장을 가속하고 있습니다. 심장병, 뇌졸중, 당뇨병 및 기타 많은 질병은 iPS 세포를 통한 치료를 통해 치료할 수 있기 때문입니다. 예를 들어, 국제당뇨병연맹(IDF)에 따르면 2021년에는 이미 5억 3,700만 명이 당뇨병을 앓고 있다고 합니다.

코로나19 팬데믹 기간 동안 연구 활동 증가는 시장에 긍정적인 영향을 미치고 있습니다. SARS CoV-2 감염으로 인해 환자들에게 많은 질병이 발생했기 때문에 전염병은 많은 부문에서 연구를 촉진했습니다. 예를 들어, 2021년 4월 미국 연구진은 코로나19 환자의 최대 25%가 심장 기능 장애를 앓고 있다고 밝혔습니다. 연구 논문을 통해 그들은 iPS 세포 유래 심장 세포가 SARS CoV-2에 노출되면 발병한다는 것을 증명했으며, 환자의 인체 부검 표본에서도 유사한 변화를 확인했습니다. 이러한 통찰력을 통해, 인공만능줄기세포(iPSC)를 약물 및 치료제 개발 플랫폼으로 활용하고 코로나19의 장기적인 영향을 관리하는데 활용할 수 있을 것으로 기대됩니다.

인공만능줄기세포는 성인의 체세포에서 유도된 후 ESC와 같은 다능성을 갖도록 재프로그래밍된 세포입니다. 이 iPS 세포는 배반포 단계에서 배아를 파괴하기 때문에 윤리적 논란의 여지가 가장 큰 배반포 단계에서 배아를 파괴하기 때문에 ESC를 사용하는 연구에 있어 윤리적으로 문제가 없는 선택임이 입증되고 있습니다. 그러나 인공만능줄기세포는 체세포의 유전자 초기화만을 수행함으로써 연구에서의 인간 배아 파괴에 대한 윤리적 문제를 해결했습니다. 이는 시장 성장을 가속하고 신약 개발, 질병 모델링, 독성 테스트 등 수많은 응용 분야를 가져왔습니다. 예를 들어, 2021년 8월 Fate Therapeutics는 iPS 세포 유래 인공 CAR-T 세포 치료제인 FT819로 임상시험 중인 FT819로 첫 환자를 치료했다고 발표했습니다. 또한, 분화 가능성, 자가 재생 가능성, 면역 조절 특성 등 독특한 특성으로 인해 재생 의학에서 인공 다능성 줄기세포의 적용을 모색하는 연구 커뮤니티의 관심이 높아지면서 시장 확대의 원동력이 되고 있습니다.

유도만능줄기세포(iPSC) 생산 시장 보고서 하이라이트

• 공정별로는 수작업 iPSC 생산 공정이 2023년 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
• 워크플로우별로는 세포 배양 부문이 2023년 37.34%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다. 세포 배양 워크플로우에는 iPSC 수집 제품, 확대 제품 및 분화 제품에서 발생하는 수익이 포함되어 있어 이 부문 시장 관련성에 기여하고 있습니다.
• 제품별로는 소모품 및 키트 부문이 2023년 40.32%의 가장 큰 매출 점유율을 차지하며 시장을 장악하고 있으며, iPSC 부문의 끊임없는 연구 개발 활동이 다양한 소모품 및 키트에 대한 수요를 주도하고 있습니다.
• 용도별로는 의약품 개발 및 탐색 부문이 2023년 43.33%로 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
• 최종 용도별로는 생명공학 및 제약 회사 부문이 2023년 59.35%의 최대 매출 점유율로 시장을 장악했으며, iPSC 제품과 함께 다양한 키트, 소모품 및 기기의 가용성 및 채택이 이 부문의 수익 창출을 촉진하고 있습니다.
• 북미가 2023년 40.98%의 가장 큰 매출 점유율을 차지하며 시장을 주도할 것으로 예상됩니다. 이 지역의 만성 질환 발병률 증가, 잘 정비된 의료 인프라, 민간 및 정부 이니셔티브에 의한 자금 지원, 전략적 비즈니스 모델이 이 시장의 수익 창출을 촉진하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 업계 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 유도만능줄기세포(iPSC) 생산 시장 : 프로세스 비즈니스 분석

• 기술 부문 대시보드
• 세계의 유도만능줄기세포(iPSC) 생산 시장 프로세스, 변동 분석
• 세계의 유도만능줄기세포(iPSC) 생산 시장 규모와 동향 분석, 프로세스별, 2018-2030년
• 수동 iPSC 생산 공정
• 자동화 iPSC 생산 공정

제5장 유도만능줄기세포(iPSC) 생산 시장 : 워크플로우 비즈니스 분석

• 워크플로우 부문 대시보드
• 세계의 유도만능줄기세포(iPSC) 생산 시장 워크플로우 변동 분석
• 세계의 유도만능줄기세포(iPSC) 생산 시장 규모와 동향 분석, 워크플로우별, 2018-2030년
• 재프로그래밍
• 세포배양
• 세포 특성 평가/분석
• 엔지니어링
• 기타

제6장 유도만능줄기세포(iPSC) 생산 시장 : 제품 비즈니스 분석

• 제품 부문 대시보드
• 세계의 유도만능줄기세포(iPSC) 생산 시장 제품 변동 분석
• 세계의 유도만능줄기세포(iPSC) 생산 시장 규모와 동향 분석, 제품별, 2018-2030년
• 기기 및 장비
• 자동화 플랫폼
• 소모품 및 키트
• 서비스

제7장 유도만능줄기세포(iPSC) 생산 시장 : 용도 비즈니스 분석

• 샘플 유형 부문 대시보드
• 세계의 유도만능줄기세포(iPSC) 생산 시장 용도 변동 분석
• 세계의 유도만능줄기세포(iPSC) 생산 시장 규모와 동향 분석, 용도별, 2018-2030년
• 의약품 개발과 발견
• 재생의료
• 독성학 연구
• 기타

제8장 유도만능줄기세포(iPSC) 생산 시장 : 최종 용도 비즈니스 분석

• 최종 용도 부문 대시보드
• 세계의 유도만능줄기세포(iPSC) 생산 시장 최종 용도 변동 분석
• 세계의 유도만능줄기세포(iPSC) 생산 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 연구 및 학술기관
• 바이오테크놀러지 및 제약회사
• 병원 및 클리닉

제9장 유도만능줄기세포(iPSC) 생산 시장 : 프로세스, 워크플로우, 제품, 용도, 최종 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 구도

• 참여 기업
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 참여 기업 개요
  • Lonza
  • Axol Bioscience Ltd.
  • Evotec
  • REPROCELL Inc.
  • STEMCELL Technologies
  • Merck KGaA
  • Fate Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Catalent, Inc
  • Applied StemCells, Inc.

제11장 애널리스트의 견해

LSH

영문 목차

영문목차

Induced Pluripotent Stem Cells Production Market Growth & Trends:

The global induced pluripotent stem cells production market size is expected to reach USD 2.76 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

Induced Pluripotent Stem Cells Production Market Report Highlights:

• By process, the manual iPSC production process segment dominated the market and accounted for the largest revenue share in 2023.
• By workflow, the cell culture segment dominated the market with the largest revenue share of 37.34% in 2023. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.
• By product, the consumables and kits segment dominated the market and accounted for the largest revenue share of 40.32% in 2023. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables & kits.
• By application, drug development & discovery segment dominated the market with the largest revenue share of 43.33% in 2023.
• By end-user, the biotechnology and pharmaceutical companies segment dominated the market with the largest revenue share of 59.35% in 2023. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment.
• North America dominated the market and accounted for the largest revenue share of 40.98% in 2023. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Process
  • 1.2.2. Workflow
  • 1.2.3. Product
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing applications of regenerative medicine
    • 3.2.1.2. Technological advancements in ipsc production
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent process control and regulatory challenges
    • 3.2.2.2. High cost of production
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Induced Pluripotent Stem Cells Production Market: Process Business Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Induced Pluripotent Stem Cells Production Market Process, Movement Analysis
• 4.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Process, 2018 to 2030 (USD Million)
• 4.4. Manual iPSC Production Process
  • 4.4.1. Global Manual iPSC Production Process Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Automated iPSC Production Process
  • 4.5.1. Global Automated iPSC Production Process Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Production Market: Workflow Business Analysis

• 5.1. Workflow Segment Dashboard
• 5.2. Global Induced Pluripotent Stem Cells Production Market Workflow Movement Analysis
• 5.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 5.4. Reprogramming
  • 5.4.1. Global Reprogramming Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Cell Culture
  • 5.5.1. Global Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cell Characterization/Analysis
  • 5.6.1. Global Cell Characterization/Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Engineering
  • 5.7.1. Global EngineeringMarket Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Production Market: Product Business Analysis

• 6.1. Product Segment Dashboard
• 6.2. Global Induced Pluripotent Stem Cells Production Market Product Movement Analysis
• 6.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 6.4. Instrument/Devices
  • 6.4.1. Global Instrument/Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Automated Platforms
  • 6.5.1. Global Automated Platforms Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Consumables & Kits
  • 6.6.1. Global Consumables & Kits Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Media
    • 6.6.2.1. Global Media Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Kits
    • 6.6.3.1. Global Kits Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. Others
    • 6.6.4.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Services
  • 6.7.1. Global Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Production Market: Application Business Analysis

• 7.1. Sample Type Segment Dashboard
• 7.2. Global Induced Pluripotent Stem Cells Production Market Application Movement Analysis
• 7.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Drug Development and Discovery
  • 7.4.1. Global Drug Development and Discovery Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Regenerative Medicine
  • 7.5.1. Global Regenerative Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Toxicology Studies
  • 7.6.1. Global Toxicology Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Induced Pluripotent Stem Cells Production Market: End Use Business Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Induced Pluripotent Stem Cells Production Market End Use Movement Analysis
• 8.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Research & Academic Institutes
  • 8.4.1. Global Research & Academic Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Biotechnology & Pharmaceutical Companies
  • 8.5.1. Global Biotechnology & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Hospitals & Clinics
  • 8.6.1. Global Hospitals & Clinics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Induced Pluripotent Stem Cells Production Market: Regional Estimates & Trend Analysis by Process, Workflow, Product, Application, & End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 9.3. North America
  • 9.3.1. North America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Saudi Arabia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. UAE Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Participant's Overview
  • 10.4.1. Lonza
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Axol Bioscience Ltd.
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Evotec
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. REPROCELL Inc.
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. STEMCELL Technologies
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Merck KGaA
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Fate Therapeutics
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Thermo Fisher Scientific, Inc.
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Catalent, Inc
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Applied StemCells, Inc.
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives

Chapter 11. Analyst View

관련자료